-

Agilent Launches Partnership with Delaware State University to Advance Diversity in Science, Technology, Engineering and Math (STEM) Fields

Agilent will fund STEM students from underrepresented groups, and provide lab instrumentation and mentorship to support postgraduate research in the life sciences

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is launching a partnership with Delaware State University (DSU), a leading historically Black university, to increase the share of underrepresented students entering STEM fields, a central mission of the company’s philanthropic work through the Agilent Foundation.

Agilent will donate $1 million in addition to new lab instrumentation to help DSU expand educational opportunities and advance research in applied chemistry, biological sciences, food science, molecular and cellular neuroscience, and related disciplines. Agilent’s support will also contribute to building research capacity of a consortium of historically Black colleges and universities (HBCUs) in the mid-Atlantic region led by Delaware State.

“DSU has a tremendous pool of talented STEM students,” said Agilent President and CEO Mike McMullen. “This partnership will help us provide direct support to these students and encourage more scholars at HBCUs across the mid-Atlantic to consider opportunities at Agilent and within the broader life sciences sector.”

Agilent’s donation comes as DSU breaks ground on a new 24,000-square-foot building for its College of Agriculture Science and Technology (CAST), which includes space for new labs.

“Many believe that this is a renaissance moment for HBCUs. It’s not,” said DSU President Dr. Tony Allen. “We’ve been doing the work for 175 years—building the most useful pipeline for African Americans to the American middle class and breaking new ground in every field of human endeavor. Great companies like Agilent understand the work and are connecting with our system for the long term, a system still producing 25% of all the Black STEM graduates in our country. Our partnership with Agilent is about making the HBCU difference today, tomorrow, and for generations to come.”

The donation will fully fund 21 graduate and undergraduate students pursuing STEM degrees. Agilent is also providing analytical lab instrumentation, supplies, services, and other infrastructure to equip CAST’s new lab space.

“DSU is making important contributions to the STEM fields, and this donation will help ensure this historically underinvested and underrepresented community is getting the resources needed to have an even greater impact,” said Gregory MacKenney, the vice president of Agilent's instrument supplies business, and an alumnus of Morgan State University and co-founder of Agilent’s networking group for Black employees.

Agilent will also provide mentorship opportunities for DSU students with Agilent scientists, engineers, and researchers and will help fund DSU’s summer internship program for STEM students.

To further support the partnership, Agilent is double-matching employee donations to HBCUs through the end of the year. The investment in HBCUs is part of Agilent’s broader philanthropic work, which focuses on increasing the pipeline of early-career professionals entering the life-sciences sector and addressing climate change and other environmental issues. It also advances the goals of Agilent’s diversity and inclusion programs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom